{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-038576","form_type":"8-K","ticker":"CCCC","cik":"0001662579","company_name":"C4 Therapeutics, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.587256+00:00","generated_at":"2026-05-17T17:45:09.016006+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"C4 Therapeutics Q2 net loss $26M; cemsidomide MM ORR 40-50%; FDA align on Phase 2 dose by YE","bullets":["Net loss of $26.0M ($0.37/share) on revenue $6.5M, down from $12.0M YoY.","Cemsidomide Phase 1 MM data: ORR 40% at 75 µg and 50% at 100 µg; well-tolerated; highest dose 100 µg.","Productive Type C meeting with FDA; registrational development expected to start early 2026; full data at IMS September 2025.","Cash $223M as of June 30, 2025; runway extended to mid-2027.","Preclinical milestone achieved under Merck KGaA collaboration; $1M earned."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-038576","json":"https://secwatch.observer/filing/0001628280-25-038576.json","markdown":"https://secwatch.observer/filing/0001628280-25-038576.md","text":"https://secwatch.observer/filing/0001628280-25-038576.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662579/000162828025038576/0001628280-25-038576-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662579/000162828025038576/cccc-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:45:09.016006+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}